Alpha Tau Medical Ltd.
DRTS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.05 | -0.74 | 0.36 | -0.14 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -37.10 | -27.49 | -19.78 | -40.04 |
| Quality | ||||
| ROIC | 50.35% | -9.35% | -13.05% | -12.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.97 | -0.18 | -0.78 | 0.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |